The italy nuclear imaging market size is projected to expand from USD 290.65 million in 2025 and USD 309.88 million in 2026 to USD 426.93 million by 2031, registering a CAGR of 6.62% between 2026 to 2031. This report is Segmented by Product (Equipment, Radioisotopes [SPECT Radioisotopes {Technetium-99m (Tc-99m) and More} and PET Radioisotopes]), Application (Cardiology, Neurology, Thyroid, Oncology, and Other Applications), End User (Hospitals, Diagnostic Imaging Centres, and Academic & Research Institutes). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Adoption of energy-efficient digital scanners tempers hospital utility overhead and aligns with EU Green Deal directives, strengthening capital-expenditure cases. Vendor service-as-a-subscription models further mitigate upfront cost, encouraging smaller Southern facilities to enter the modality mix, albeit at slower cadence. Continuous performance upgrades, such as extended axial field-of-view detectors, are forecast to keep equipment leading Italy nuclear imaging market revenues through 2031.
Italy Nuclear Imaging Market Trends and Insights
Rising Incidence of Cancer & CVD
New cancer diagnoses in Italy climbed to 390,700 in 2022, up 14,100 from 2020, with breast, colorectal, and lung cancers topping incidence charts. Mortality projections for 2025 signal a 3.5% national decline, yet aging cohorts continue to push demand for precise staging and therapy monitoring through PET/CT imaging. Hybrid modalities now influence treatment decisions in more than 42% of differentiated thyroid carcinoma cases, highlighting clinical reliance on molecular imaging. Cardiovascular disease persists as the primary mortality cause, and Tc-99m SPECT remains routine for perfusion assessment, reinforcing baseline procedure volumes.Growing Adoption of Hybrid PET/CT & SPECT/CT
Italian participation in Europe-wide multimodality imaging surveys shows steady acceleration of PET/CT rollouts, with 18F-FDG dominating tracer use. University of Padua researchers recorded 100% sensitivity and 96% accuracy for [18F]FDG PET/MRI in hepatocellular carcinoma surveillance after liver transplantation, outperforming conventional protocols. A 502-patient multicenter trial demonstrated that segmental PET/CT lowers radiation dose without diagnostic compromise in solitary pulmonary nodules, supporting guideline updates. Northern centers advance niche tracers such as 64CuCl2 for bladder cancer staging, reinforcing regional leadership.High Equipment Capital & Maintenance Costs
PET/CT platforms cost EUR 4 million (USD 4.68 million) and frequently require bunker upgrades, straining hospital budgets that already allocate nearly 77.45% of operational spending to facility management. Aging buildings, 70% surpassing their designed 50-year lifecycle, magnify retrofit expenses, especially in Southern provinces with fewer tertiary centers. Maintenance contracts with multinational OEMs add long-term overhead, prompting some regions to defer scanner refresh cycles and rely on referral flows to Northern hubs.Other drivers and restraints analyzed in the detailed report include:
- Favorable Reimbursement Framework
- Increase in Public-Private Investment for Nuclear-Medicine Suites
- Mo-99/Tc-99m Supply Bottlenecks
Segment Analysis
Equipment retained 63.55% Italy nuclear imaging market share in 2025 as hospitals prioritized PET/CT and SPECT/CT replacements to meet hybrid-imaging demand. Lombardy, Veneto, and Emilia-Romagna collectively host the densest scanner fleets, benefiting from consistent SSN reimbursements and regional budget surpluses. The radioisotope segment advances at a 6.75% CAGR, buoyed by expanding Ga-68 and Lu-177 pipelines that support theranostic protocols. Cyclotron-based production shortens supply chains and elevates the Italy nuclear imaging market size for isotopes, particularly as LARAMED scales multi-curie outputs. Northern laboratories integrate artificial-intelligence-driven QC systems to optimize batch scheduling and reduce waste, a practice expected to cascade nationwide.Adoption of energy-efficient digital scanners tempers hospital utility overhead and aligns with EU Green Deal directives, strengthening capital-expenditure cases. Vendor service-as-a-subscription models further mitigate upfront cost, encouraging smaller Southern facilities to enter the modality mix, albeit at slower cadence. Continuous performance upgrades, such as extended axial field-of-view detectors, are forecast to keep equipment leading Italy nuclear imaging market revenues through 2031.
Complete Report Scope:
- By Product
- Equipment
- Radioisotopes
- SPECT Radioisotopes
- Technetium-99m (Tc-99m)
- Thallium-201 (Tl-201)
- Gallium-67 (Ga-67)
- Iodine-123 (I-123)
- Other SPECT Isotopes
- PET Radioisotopes
- Fluorine-18 (F-18)
- Rubidium-82 (Rb-82)
- Other PET Isotopes
- SPECT Radioisotopes
- By Application
- Cardiology
- Neurology
- Thyroid
- Oncology
- Other Applications
- By End User
- Hospitals
- Diagnostic Imaging Centres
- Academic & Research Institutes
List of Companies Covered in this Report:
- Alliance Medical (Life Healthcare Group)
- Bracco Imaging S.p.A.
- Cardinal Health
- Curium Pharma
- GE Healthcare
- Koninklijke Philips
- NTP Radioisotopes
- Siemens Healthineers
- Telix Pharmaceuticals Ltd.
- Canon
- FUJIFILM
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alliance Medical (Life Healthcare Group)
- Bracco Imaging S.p.A.
- Cardinal Health Inc.
- Curium Pharma
- GE HealthCare
- Koninklijke Philips N.V.
- NTP Radioisotopes
- Siemens Healthineers
- Telix Pharmaceuticals Ltd.
- Canon Medical Systems Corporation
- Fujifilm Holdings Corporation
